PECULIAR: An Open Label, Monocenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat, Preceding Radical Cystectomy, for Patients With Muscle-invasive Bladder Cancer.
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms PECULIAR
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 Mar 2018 New trial record
- 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.